Unmet needs in female contraceptives market persist, says analyst
The current unmet needs in the female contraceptives market are similar to those that were present 10 years ago. Currently, marketed contraceptives carry the risk of irregular bleeding patterns, weight gain, changes in mood, depression, migraine or headache, nausea, and acne.
Side effects are one of the main reasons why patients may decide to discontinue contraceptive use, leading to unintended pregnancies. The market still lacks therapeutics that provide better safety, says pharma analytics company Global Data.
Key opinion leaders (KOLs) interviewed by GlobalData have expressed the opinion that some women are hesitant to take hormonal contraceptives because of the associated side effects. The unmet need for non-hormonal contraception is a significant concern for individuals who wish to avoid hormonal contraceptives for several reasons, such as side effects, personal preferences, or religious beliefs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze